SEC Form 4 · accession 0000899243-18-013279
AILERON THERAPEUTICS INC · ALRN
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
John P Longenecker Ph.D.
Officer — President and CEO
Period of report
May 15, 2018
Accepted (ET)
May 17, 2018 · 6:16 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001420565
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (right to buy)F1 | $5.50 | May 15, 2018 | A | 30,000 | A | — | May 14, 2028 | Common Stock | 30,000 | 30,000 | D |
Explanation of responses
- F1This option was granted on May 15, 2018. The shares underlying the option are scheduled to vest in full on the earlier of (i) September 15, 2018 or (ii) the date on which Dr. Longenecker's employment is terminated in connection with the Company's hiring of a new chief executive officer.